Welcome to the DDRiver™ Clinical Trials Program

If you are an HCP, click on “I’m a Healthcare Professional"

If you are a patient, please click on “I’m not a Healthcare Professional”

Leaving DDRiver™ website

You are leaving DDRiver™ Clinical Trials page. This link will take you to a website where our Terms of Use do not apply. EMD Serono does not control the content of these websites.

mask group1 Actor Portrayals

DDRiverTM Clinical Trials Program

The drugs in the DDRiverTM clinical trials program are under clinical investigation and have not yet been proven to be safe and effective. There is no guarantee that any therapies in the clinical trials program will be approved in the sought-after indication by any health authority worldwide.

The DDRiverTM website only highlights DDR inhibitor studies that are sponsored by EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany, in the US and Canada.

group 145 Actor Portrayals

Programs

Logo1

Tuvusertib (M1774) in Solid Tumors

Tuvusertib (M1774) is an investigational orally administered inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein kinase1-3

logo 2

Tuvusertib (M1774) in Solid Tumors

Tuvusertib (M1774) is an investigational orally administered inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein kinase1-3

logo

M4076 in Solid Tumors  

M4076 is an investigational orally administered ATP-competitive inhibitor of ataxia telangiectasia mutated (ATM) protein kinase4,5

Visit clinicaltrials.gov to learn about more our DDR inhibitor studies conducted in collaboration with academic partners.

References

1. Roidos P, et al. Nat Commun. 2020;11(1):4077; 2. ClinicalTrials.gov. Accessed June 28, 2023. https://clinicaltrials.gov/ct2/show/NCT04170153; 3. ClinicalTrials.gov. Accessed June 28, 2023. https://clinicaltrials.gov/ct2/show/NCT05396833; 4. Zimmermann A, et al. Mol Cancer Ther. 2022;21(6):859-870; 5. ClinicalTrials.gov. Accessed June 28, 2023. https://clinicaltrials.gov/ct2/show/NCT04882917.